Evidence map›Paper›PMID 32492417›Full record

ArticleCell reports2020

Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer.

Lisa M Becker, Joyce T O'Connell, Annie P Vo, Margo P Cain, Desiree Tampe, Lauren Bizarro, Hikaru Sugimoto, Anna K McGow, John M Asara, Sara Lovisa and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed, 2 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

198 citing papers in PubMed, 2 syntheses or guidelines pooled it, 273 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Tumorigenesis and Tumor Microenvironment in Lung Cancer.Current issues in molecular biology · 2026
    Review
  19. Review
  20. Review

138 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Lisa M BeckerDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Joyce T O'ConnellDivision of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Annie P VoDivision of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Margo P CainDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Desiree TampeDepartment of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, Göttingen 37075, Germany.
Lauren BizarroDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Hikaru SugimotoDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Anna K McGowDepartment of Radiology, Brigham and Women's Hospital, Boston, MA 02215, USA.
John M AsaraDivision of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02215, USA.
Sara LovisaDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Kathleen M McAndrewsDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Rafal ZielinskiDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Philip L LorenziMetabolomics Core Facility, Department of Bioinformatics & Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael ZeisbergDepartment of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, Göttingen 37075, Germany.
Sughra RazaDepartment of Radiology, Brigham and Women's Hospital, Boston, MA 02215, USA.
Valerie S LeBleuDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA; Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. Electronic address: valerie.lebleu@northwestern.edu.
Raghu KalluriDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA; Department of Bioengineering, Rice University, Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: rkalluri@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USHarvard University · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USUniversity of Göttingen · DE

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9M
RESEARCH TRAINING IN GASTROENTEROLOGYT32DK007760 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KELLY, CIARAN P · 1999 to 2019
$4.6M
Targeting Pericytes in CancerR01CA155370 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2011 to 2015
$1.7M
Computational Tools for Analysis and Visualization of Quality Control Issues in Metabolomic DataU01CA235510 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AKBANI, REHAN, BROOM, BRADLEY MCINTOSH · 2018 to 2021
$1.6M
Role of Fibroblasts in CancerR01CA125550 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KALLURI, RAGHU · 2008 to 2010
$1.1M
Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and MetabolomicsS10OD012304 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAWKE, DAVID H · 2013 to 2013
$877k
NCI NIH HHS P01 CA120964NCI NIH HHS P30 CA006516NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA125550NCI NIH HHS R01 CA155370NCI NIH HHS U01 CA235510NIDDK NIH HHS T32 DK007760NIH HHS S10 OD012304
6 · The paper itself

Abstract

The mechanistic contributions of cancer-associated fibroblasts (CAFs) in breast cancer progression remain to be fully understood. While altered glucose metabolism in CAFs could fuel cancer cells, how such metabolic reprogramming emerges and is sustained needs further investigation. Studying fibroblasts isolated from patients with benign breast tissues and breast cancer, in conjunction with multiple animal models, we demonstrate that CAFs exhibit a metabolic shift toward lactate and pyruvate production and fuel biosynthetic pathways of cancer cells. The depletion or suppression of the lactate production of CAFs alter the tumor metabolic profile and impede tumor growth. The glycolytic phenotype of the CAFs is in part sustained through epigenetic reprogramming of HIF-1α and glycolytic enzymes. Hypoxia induces epigenetic reprogramming of normal fibroblasts, resulting in a pro-glycolytic, CAF-like transcriptome. Our findings suggest that the glucose metabolism of CAFs evolves during tumor progression, and their breast cancer-promoting phenotype is partly mediated by oxygen-dependent epigenetic modifications.

Indexed as

EpigenomicsActinsAnimalsBreast NeoplasmsCancer-Associated FibroblastsCell Line, TumorFemaleGlucoseGlycolysisHumansHypoxia-Inducible Factor 1, alpha SubunitLactic AcidMiceMice, Inbred BALB CMice, TransgenicMonocarboxylate Transport Protein 1Actinsalpha-smooth muscle actin, mouseGlucoseHypoxia-Inducible Factor 1, alpha SubunitLactic AcidMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersPdk4 protein, mousePyruvate Dehydrogenase Acetyl-Transferring KinasePyruvic AcidRNA, Small InterferingSymportersbreast cancercancer-associated fibroblastsepigenetic alterationshypoxiametabolism

Identifiers

PMID32492417
PMCPMC7339325
OpenAlexW3029079472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.